|
POLR3A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.98069998975137E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.4083999996043E-07 |
| Normal-vs-Stage2 |
2.371400E-04 |
| Normal-vs-Stage3 |
9.51609999688685E-08 |
| Normal-vs-Stage4 |
3.89419999580198E-08 |
| Stage1-vs-Stage2 |
9.684200E-01 |
| Stage1-vs-Stage3 |
1.645170E-01 |
| Stage1-vs-Stage4 |
2.306000E-02 |
| Stage2-vs-Stage3 |
3.511800E-01 |
| Stage2-vs-Stage4 |
1.053760E-01 |
| Stage3-vs-Stage4 |
3.910600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.31999999714228E-08 |
| Normal-vs-AfricanAmerican |
8.696800E-03 |
| Normal-vs-Asian |
2.812300E-04 |
| Caucasian-vs-AfricanAmerican |
4.169400E-01 |
| Caucasian-vs-Asian |
7.098800E-01 |
| AfricanAmerican-vs-Asian |
6.290000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.42239997558136E-09 |
| Normal-vs-Female |
2.16060000002294E-07 |
| Male-vs-Female |
6.722500E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.64710000003254E-06 |
| Normal-vs-Age(41-60Yrs) |
7.5003000032936E-08 |
| Normal-vs-Age(61-80Yrs) |
1.53649999945493E-07 |
| Normal-vs-Age(81-100Yrs) |
7.943000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.227800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.538200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.105000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.395800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.700400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.569800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.102100E-02 |
| Classical-VS-Follicular |
1.264470E-02 |
| Classical-VS-Other |
2.301000E-01 |
| Classical-VS-Normal |
1.24219999997344E-06 |
| Tall-VS-Follicular |
8.605400E-01 |
| Tall-VS-Other |
8.064600E-01 |
| Tall-VS-Normal |
1.77421999999483E-05 |
| Follicular-VS-Other |
7.621800E-01 |
| Follicular-VS-Normal |
2.0831000002719E-07 |
| Other-VS-Normal |
8.461600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.15369999945203E-07 |
| Normal-vs-N1 |
1.39760000017475E-07 |
| N0-vs-N1 |
1.096400E-01 |
|
|
